T. Rowe Price Associates, Inc. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 5,088,495 shares of ORIC Pharmaceuticals Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Associates, Inc. reported beneficial ownership of 5,088,495 shares of ORIC Pharmaceuticals Inc. common stock.
- Percent of class: The reported stake represents 4.9% of the outstanding class of common stock.
- Sole voting power: T. Rowe Price Associates, Inc. reported sole voting power over 5,079,985 shares.
- Sole dispositive power: The filing disclosed sole dispositive power over 5,088,495 shares, with no shared voting or dispositive power reported.
- Triggering event date: The date of the event requiring this filing was September 30, 2026.
- Filer classification: T. Rowe Price Associates, Inc. is identified as an investment adviser, organized in Maryland, with offices at 1307 Point Street, Baltimore, MD 21231.
T. Rowe Price Associates Discloses Amended Ownership Position in ORIC Pharmaceuticals
T. Rowe Price Associates, Inc. submitted Amendment No. 1 to its Schedule 13G regarding its holdings in ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), whose principal executive offices are located at 240 E. Grand Ave., 2nd Floor, South San Francisco, CA 94080. The filing, signed by Ellen York, Vice President, was dated November 16, 2026, and reflects ownership as of a triggering event on September 30, 2026.
According to the filing, T. Rowe Price Associates, Inc. beneficially owns a total of 5,088,495 shares of ORIC Pharmaceuticals common stock (CUSIP 68622P109), equal to 4.9% of the class. The firm reported sole voting power over 5,079,985 shares and sole dispositive power over the full 5,088,495 shares. No shared voting or dispositive power was reported. The filing notes ownership of 5 percent or less of the class under Item 5.
In its certification, T. Rowe Price Associates, Inc. stated that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The firm also expressly denied that the filing of the Schedule 13G constitutes an admission that it is the beneficial owner of the securities referenced, as stated in the filing's certification language.
What Was Disclosed
T. Rowe Price Associates, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 5,088,495 shares, or 4.9%, of ORIC Pharmaceuticals Inc. common stock as of September 30, 2026, with sole voting and dispositive power and no shared ownership.



Please wait processing your request...